Very interesting and could be another reason why Afrezza could become a first line treatment for type 2 diabetes. From the article:

'That's because the most common prescription for type 2 diabetes—a drug called metformin—ramps up activation of AMPK. Type 2 diabetes has long been considered a risk factor for Alzheimer's, and Polleux thinks metformin might be the link.

"We have direct evidence that metformin overactives AMPK in neurons, and that is toxic to neurons," he said.'